ଡାକ୍ଲାଟାସଭିର/ସୋଫୋସବୁଭିର

ଡାକ୍ଲାଟାସଭିର/ସୋଫୋସବୁଭିର
	Sovodak 60/400
Combination of
Daclatasvir	NS5A inhibitor
Sofosbuvir	NS5B (RNA polymerase) inhibitor
Clinical data
Trade names	Darvoni, Sovodak
Routes of; administration	By mouth

ଡାକ୍ଲାଟାସଭିର/ସୋଫୋସବୁଭିର (DCV/SOF) ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ସୋଭୋଡାକ୍ ବ୍ରାଣ୍ଡ ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ହେପାଟାଇଟିସ ସି ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ମିଶ୍ରଣ ।^[୧] ଏହା ଏକ ପ୍ରଥମ ଧାଡ଼ିର ଚିକିତ୍ସା ଏବଂ ସମସ୍ତ ଉପପ୍ରକାର ବିରୁଦ୍ଧରେ ପ୍ରଭାବଶାଳୀ ।^[୨] ଏହା ୯୦% ରୁ ଅଧିକ ପ୍ରଭାବଶାଳୀ ଅଟେ ।^[୧] ଯେଉଁମାନେ ଅତି କମରେ ୩ ବର୍ଷ ବୟସରୁ ଏହା ବ୍ୟବହାର କରାଯାଇପାରେ ।^[୩] ଏହା ସାଧାରଣତଃ ଦିନକୁ ଥରେ ୧୨ ସପ୍ତାହ ପାଇଁ ଗୋଟିଏ ବଟିକା ଆକାରରେ କିମ୍ବା ଅଲଗା ଅଲଗା ଭାବରେ ଗ୍ରହଣ କରାଯାଏ ।^[୪] ^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ଥକାପଣ, ଅଇ, ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୪] ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ଅସାଧାରଣ ଅଟେ | ^[୪] ଗର୍ଭାବସ୍ଥାରେ ଡାକ୍ଲାଟାସଭିର ଏବଂ ସୋଫୋସ୍ବୁଭିରର ବ୍ୟବହାର କ୍ଷତିକାରକ ବୋଲି ଜଣାପଡି ନାହିଁ କିନ୍ତୁ ଭଲ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ | ^[୫] ^[୬] ଏଥିରେ ଡାକ୍ଲାଟାସଭିର, ଏକ ଭୂତାଣୁ ଏନଏସ୫ଏ ଅବରୋଧକ (NS5A) ^[୭] ଏବଂ ସୋଫୋସବୁଭିର, ଭୂତାଣୁ ଆରଏନଏ ପଲିମରେଜର (NS5B) ଏକ ନ୍ୟୁକ୍ଲିଓଟାଇଡ ପ୍ରତିରୋଧକ ଥାଏ ।^[୮]

୨୦୨୨ ମସିହା ସୁଦ୍ଧା ସ୍ୱଳ୍ପ ଏବଂ ମଧ୍ୟମ ଆୟକାରୀ ଦେଶମାନଙ୍କରେ ହେପାଟାଇଟିସ୍ ସି ପାଇଁ ଏହା ଏକ ସାଧାରଣ ବ୍ୟବହୃତ ଚିକିତ୍ସା ।^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ମିଶ୍ରଣ କେବେ ଅନୁମୋଦିତ ହୋଇନାହିଁ ଏବଂ ଡାକ୍ଲାଟାଭିର ବିକ୍ରୟ ୨୦୧୯ରେ ବନ୍ଦ ହୋଇଯାଇଥିଲା ^[୯] ଏହା ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧ ତାଲିକାରେ ଅଛି ।^[୧୦] ଏହା ସର୍ବନିମ୍ନ ମହଙ୍ଗା ଆଧୁନିକ ହେପାଟାଇଟିସ୍ ସି ଚିକିତ୍ସା ଯାହାର ମୂଲ୍ୟ ୫୦ରୁ ୧୪୦୦ ଡଲାର ଅଟେ | ^[୪] ^[୨]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ Pol S, Corouge M, Vallet-Pichard A (2016). "Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–26. doi:10.2147/HMER.S62014. PMC 4786064. PMID 27019602.{{cite journal}}: CS1 maint: unflagged free DOI (link)
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Hepatitis C". www.who.int (in ଇଂରାଜୀ). Archived from the original on 26 May 2020. Retrieved 2 December 2022.
↑ "WHO publishes updated guidance on hepatitis C infection – with new recommendations on treatment of adolescents and children, simplified service delivery and diagnostics". www.who.int (in ଇଂରାଜୀ). Archived from the original on 6 October 2022. Retrieved 2 December 2022.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Application for Inclusion of Sofosbuvir/Daclatasvir on the WHO Model List of Essential Medicines for Children (EMLc)" (PDF). Archived (PDF) from the original on 2 December 2022. Retrieved 2 December 2022.
↑ "Daclatasvir (Daklinza) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 6 December 2021. Retrieved 2 December 2022.
↑ "Sofosbuvir (Sovaldi) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 February 2020. Retrieved 2 December 2022.
↑ "Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC)". Electronic Medicines Compendium. September 2016. Archived from the original on 2016-11-09.
↑ "Sovaldi 400 mg film coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
↑ Abraham, GM; Obley, AJ; Humphrey, LL; Qaseem, A; Scientific Medical Policy Committee of the American College of, Physicians; Centor, RM; Akl, E; Forceia, MA; Haeme, R (January 2021). "World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians". Annals of internal medicine. 174 (1): 98–100. doi:10.7326/M19-3860. PMID 33017566. {{cite journal}}: |last5= has generic name (help)
↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[Pol2016-1] ୧.୦ ^୧.୧ ^୧.୨ Pol S, Corouge M, Vallet-Pichard A (2016). "Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–26. doi:10.2147/HMER.S62014. PMC 4786064. PMID 27019602.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[WHO2022-2] ୨.୦ ^୨.୧ ^୨.୨ "Hepatitis C". www.who.int (in ଇଂରାଜୀ). Archived from the original on 26 May 2020. Retrieved 2 December 2022.

[3] "WHO publishes updated guidance on hepatitis C infection – with new recommendations on treatment of adolescents and children, simplified service delivery and diagnostics". www.who.int (in ଇଂରାଜୀ). Archived from the original on 6 October 2022. Retrieved 2 December 2022.

[Peds2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Application for Inclusion of Sofosbuvir/Daclatasvir on the WHO Model List of Essential Medicines for Children (EMLc)" (PDF). Archived (PDF) from the original on 2 December 2022. Retrieved 2 December 2022.

[5] "Daclatasvir (Daklinza) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 6 December 2021. Retrieved 2 December 2022.

[6] "Sofosbuvir (Sovaldi) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 February 2020. Retrieved 2 December 2022.

[7] "Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC)". Electronic Medicines Compendium. September 2016. Archived from the original on 2016-11-09.

[8] "Sovaldi 400 mg film coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Archived from the original on 10 November 2016. Retrieved 10 November 2016.

[Abra2021-9] Abraham, GM; Obley, AJ; Humphrey, LL; Qaseem, A; Scientific Medical Policy Committee of the American College of, Physicians; Centor, RM; Akl, E; Forceia, MA; Haeme, R (January 2021). "World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians". Annals of internal medicine. 174 (1): 98–100. doi:10.7326/M19-3860. PMID 33017566. {{cite journal}}: |last5= has generic name (help)

[WHO22nd-10] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]